Trial · NCT07466238
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
NCT07466238, Not applicable, Recruiting, Peking University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer. Trials, record NCT07466238. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07466238
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
- NCT number
- NCT07466238
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Peking University
- Conditions
- Biliary Tract Cancer (BTC)
- Interventions
- HAIC(GOLF), Bevacizumab, PD-1/PD-L1 inhibitor, HAIC (FOLFOX), Gemcitabin, De-escalation strategy, Second-line treatment
- First posted
- 2026-03-12
- Last updated
- 2026-05-08
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | OS | From date of treatment beginning until the date of death from any cause, assessed up to 36 months. | The time from treatment initiation to death due to any cause |
| Primary | clinical complete response rate | From date of treatment beginning until the date of first documented progression disease, up to 36 months. | The proportion of participants in the analysis population who have clinical complete response (CR) determined by investigators using mRECIST criteria at any time during the study. |
| Secondary | PFS | From date of treatment beginning until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months. | The time from treatment initiation to the first documented disease progression or death due to any cause, whichever occurs firstly. |
| Secondary | ORR | From date of treatment beginning until the date of first documented progression disease, up to 36 months. | The proportion of participants in the analysis population who have complete response (CR) or partial response (PR) determined by investigators using mRECIST criteria at any time during the study. |
| Secondary | Number of patients with treatment-related adverse events | From date of treatment beginning until the date of study treatment completion, up to 36 months. | Number of patients with AE, treatment-related AE (TRAE), serious adverse event (SAE) assessed by CTCAE v5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07466238
GET https://conductscience.org/api/trials/v1/NCT07466238/registered